{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-21-004750","form_type":"8-K","ticker":"ACET","cik":"0001720580","company_name":"Adicet Bio, Inc.","filed_at":"2021-11-18T23:59:59+00:00","discovered_at":"2026-05-14T18:04:13.824403+00:00","generated_at":"2026-06-28T07:03:07.776953+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Adicet Bio appoints Dr. Michael Kauffman to board of directors","bullets":["Appointed Michael Kauffman, M.D., Ph.D. to Board, effective Nov 17, 2021.","Dr. Kauffman is independent and will serve on the Nominating and Corporate Governance Committee.","Received option to purchase 37,000 shares at $9.39, vesting over 36 months.","Over 20 years industry experience; co-founder and former CEO of Karyopharm; led Velcade development.","Fills vacancy; board now includes three NCG committee members."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-21-004750","json":"https://secwatch.observer/filing/0000950170-21-004750.json","markdown":"https://secwatch.observer/filing/0000950170-21-004750.md","text":"https://secwatch.observer/filing/0000950170-21-004750.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1720580/000095017021004750/0000950170-21-004750-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1720580/000095017021004750/acet-20211117.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T07:03:07.776953+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"016b71cb8c","claim":"Michael Kauffman was appointed as Director at Adicet Bio, Inc..","evidence_excerpt":"On November 17, 2021, upon the recommendation of the Nominating and Corporate Governance Committee (the “NCG Committee”) of the board of directors (the “Board”) of Adicet Bio, Inc. (the “Company”), the Board appointed Michael Kauffman, M.D., Ph.D., to join the Board, effective as of November 17, 2021.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1720580/000095017021004750/0000950170-21-004750-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}